HOME >> BIOLOGY >> NEWS
Merck CEO Raymond Gilmartin to lecture at NJIT

Raymond V. Gilmartin, chairman, president and chief executive officer of Merck and Co., Inc., will visit New Jersey Institute of Technology (NJIT) on Feb. 23 to deliver a lecture titled "A Prescription for Change in U.S. Health Care."

As more and more Americans come to rely on prescription drugs to meet their health care needs, the pharmaceutical industry is receiving increasing attention from policy makers at every level. Gilmartin will discuss the ongoing challenges facing the U.S. pharmaceutical industry, with particular focus on the areas of access, affordability, innovation and quality of care.

Merck and Co., Inc. is one of the most respected and successful drug makers in the world. Headquartered in Whitehouse Station, Merck employs nearly 64,000 people worldwide. Merck's global sales were $22.9 billion in 2004.

Since the company was founded in 1891, Merck researchers have pioneered innovations for treating serious diseases a tradition that produced such major medical advances as penicillin, streptomycin and cortisone, among others.

Merck is also well known for its philanthropy. For nearly 20 years, Merck has donated a drug to treat river blindness in Africa and Latin America. The company responded to the recent tsunami disaster by pledging more than $10 million in aid and supplies. Nearer to home, Merck has contributed more than $20 million to the Merck Institute for Science Education, which partners with New Jersey and Pennsylvania school districts to improve science and math education.

Prior to joining Merck in 1994, Gilmartin was chairman, president and chief executive officer of Becton Dickinson. He received a bachelor's degree in electrical engineering from Union College in 1963 and an MBA from Harvard Business School in 1968. He serves on the boards of General Mills, Inc. and the Microsoft Corporation. He is chairman of the Board of Directors of The United Negro College Fund and is a trustee of the Healthcare Le
'"/>

Contact: Robert Florida
florida@njit.edu
973-596-5203
New Jersey Institute of Technology
16-Feb-2005


Page: 1 2

Related biology news :

1. Merck and AAAS announce 2007 winners of Outstanding Undergraduate Research Programs
2. Harvard Medical signs agreement with Merck to develop potential therapy for macular degeneration
3. Merck and AAAS announce 2006 winners for Outstanding Undergraduate Research Programs
4. Researchers gain support from Merck Sharp & Dohme for novel area of diabetes research
5. Nobel Laureate Sydney Brenner receives 2005 UCSD/Merck Life Science Achievement Award
6. Merck / AAAS announce 2005 winners for outstanding undergraduate research programs
7. Protein tyrosine phosphatases to be topic of ASBMB-Merck Award lecture
8. Award lectures for ASBMBs 2007 Annual Meeting
9. AACR establishes new lecture in honor of Princess Takamatsu
10. National Academies Advisory: March 5 lecture on ocean acidification
11. Becker to deliver plenary lecture at plasma science meeting

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Merck CEO Raymond Gilmartin lecture NJIT

(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... 2014   EyeLock Inc. , a market ... MorphoTrust USA (Safran), a leading U.S. provider ... strategic partnership to offer comprehensive biometric identity solutions ... airport screening and financial services markets. ... consumers through a nationwide network of 1,100 IdentoGO® ...
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
(Date:11/21/2014)... The report, "Synthetic Biology ... Cloning kits), Technology (Bioinformatics, Nanotechnology, Gene Synthesis, ... Bioremediation) - Global Forecast to 2018", analyses ... opportunities, and challenges. , Browse 99 market ... 185 pages and in-depth TOC of the ...
(Date:11/21/2014)... Arkansas (PRWEB) November 20, 2014 ... Pinnacle Ozone Solutions, LLC (Pinnacle), and PCI, Inc., ... announced that they have been selected to provide ... of Fayetteville, Arkansas Paul R. Noland Wastewater Treatment. ... BlueInGreen’s patented HyDOZ® gas dissolution technology, ...
(Date:11/21/2014)... Dallas, Texas (PRWEB) November 21, 2014 ... China Sodium Ferrocyanide Industry” is a professional and ... it provides Sodium ferrocyanide information, like its ... well as industry overview. This report covers the ... well as global (such as the US, Europe, ...
(Date:11/21/2014)... DIEGO , Nov. 20, 2014 ... has been dosed in its Phase 1 trial ... cisplatin for the treatment of malignant pleural mesothelioma ... Group is conducting clinical trials on ADI-PEG 20, ... agents, for the treatment of several other indications, ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
Cached News: